Engineered NKG2C+ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome
Kyle B. Lupo, M. Kazim Panjwani, Aya G. Halawi, Sanam Shahid, Rosa Sottile, Clara Lawry, Gabryelle Kolk, Theodota Kontopoulos, Anthony F. Daniyan, Smita S. Chandran, Christopher Austin Klebanoff, Katharine C. Hsu
This study shows that engineered NKG2C+ NK-like T cells have better antitumor effects and lower cytokine release syndrome risk than conventional CAR-T and CAR-NK cells.
Journal of Clinical Investigation · Oct 20, 2026Peer-reviewedImmunology